Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 25;59(6):1023.
doi: 10.3390/medicina59061023.

Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon

Affiliations

Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon

Niaz Ali et al. Medicina (Kaunas). .

Abstract

Background and Objectives: We have recently reported that stains have calcium channel blocking activity in isolated jejunal preparations. In this study, we examined the effects of atorvastatin and fluvastatin on blood vessels for a possible vasorelaxant effect. We also studied the possible additional vasorelaxant effect of atorvastatin and fluvastatin, in the presence of amlodipine, to quantify its effects on the systolic blood pressure of experimental animals. Materials and Methods: Atorvastatin and fluvastatin were tested in isolated rabbits' aortic strip preparations using 80mM Potassium Chloride (KCl) induced contractions and 1 micro molar Norepinephrine (NE) induced contractions. A positive relaxing effect on 80 mM KCl induced contractions were further confirmed in the absence and presence of atorvastatin and fluvastatin by constructing calcium concentration response curves (CCRCs) while using verapamil as a standard calcium channel blocker. In another series of experiments, hypertension was induced in Wistar rats and different test concentrations of atorvastatin and fluvastatin were administered in their respective EC50 values to the test animals. A fall in their systolic blood pressure was noted using amlodipine as a standard vasorelaxant drug. Results: The results show that fluvastatin is more potent than amlodipine as it relaxed NE induced contractions where the amplitude reached 10% of its control in denuded aortae. Atorvastatin relaxed KCL induced contractions with an amplitude reaching 34.4% of control response as compared to the amlodipine response, i.e., 39.1%. A right shift in the EC50 (Log Ca++ M) of Calcium Concentration Response Curves (CCRCs) implies that statins have calcium channel blocking activity. A right shift in the EC50 of fluvastatin with relatively less EC50 value (-2.8 Log Ca++ M) in the presence of test concentration (1.2 × 10-7 M) of fluvastatin implies that fluvastatin is more potent than atorvastatin. The shift in EC50 resembles the shift of Verapamil, a standard calcium channel blocker (-1.41 Log Ca++ M). Conclusions: Atorvastatin and fluvastatin relax the aortic strip preparations predominantly through the inhibition of voltage gated calcium channels in high molar KCL induced contractions. These statins also inhibit the effects of NE induced contractions. The study also confirms that atorvastatin and fluvastatin potentiate blood pressure lowering effects in hypertensive rats.

Keywords: amlodipine; atorvastatin; calcium channel blocking activity; fluvastatin; statins; verapamil.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effects of atorvastatin on isolated aortic strip preparations to show relaxant effects in intact and denuded tissues. (A) Effects of atorvastatin on KCL-induced contractions in isolated aortic strip preparations to show relaxant effects in denuded tissues. (B) Effects of atorvastatin on KCL-induced contractions in isolated aortic strip preparations to show relaxant effects in intact tissues. (C) Effects of atorvastatin on Nor-Epinephrine induced contractions in isolated aortic strip preparations to show relaxant effects in denuded tissues (all values are mean ± SD, n = 4). (D) Effects of atorvastatin on Nor-Epinephrine induced in isolated aortic strip preparations to show relaxant effects in intact tissues. All values are mean ± SD, n = 4.
Figure 2
Figure 2
Effects of fluvastatin on isolated aortic strip preparations to show relaxant effects in intact and denuded tissues. (A) Effects of Fluvastatin on KCL-induced contractions in isolated aortic strip preparations to show relaxant effects in denuded tissues. (B) Effects of Fluvastatin on KCL-induced contractions in isolated aortic strip preparations to show relaxant effects in intact tissues. (C) Effects of Fluvastatin on Nor-Epinephrine induced contractions in isolated aortic strip preparations to show relaxant effects in denuded tissues. (D) Effects of Fluvastatin on Nor-Epinephrine induced in isolated aortic strip preparations to show relaxant effects in intact tissues. All values are mean ± SD, n = 4.
Figure 3
Figure 3
Effects of amlodipine on isolated aortic strip preparations to show relaxant effects in intact and denuded tissues. (A) Effects of amlodipine on KCL-induced contractions in isolated aortic strip preparations to show relaxant effects in denuded tissues. (B) Effects of amlodipine on KCL-induced contractions in isolated aortic strip preparations to show relaxant effects in intact tissues. (C) Effects of amlodipine on Nor-Epinephrine induced contractions in isolated aortic strip preparations to show relaxant effects in denuded tissues. (D) Effects of amlodipine on Nor-Epinephrine induced in isolated aortic strip preparations to show relaxant effects in intact tissues. All values are mean ± SD, n = 4.
Figure 4
Figure 4
CCRCs in the absence and presence of statins. (A) To show construction of CCRCs in the absence and presence of different concentrations of atorvastatin in isolated aortic strip preparations (all values are mean ± SD, n = 4). (B) To show construction of CCRCs in the absence and presence of different concentrations of fluvastatin in isolated aortic strip preparations (all values are mean ± SD, n = 4). (C) To show construction of CCRCs in the absence and presence of different concentrations of verapamil in isolated aortic strip preparations (all values are mean ± SD, n = 4).
Figure 5
Figure 5
To show additional effect of atorvastatin and fluvastatin on the blood pressure lowering effect of amlodipine (all values are mean ± SD, n = 4) using Paired t-test at 95% Confidence Interval. (A) To show additional effect of atorvastatin with amlodipine on systolic Blood pressure. (B) To show additional effect with fluvastatin with amlodipine on systolic Blood pressure. (C) To show effect of amlodipine on systolic Blood pressure.

Similar articles

Cited by

References

    1. Organization WHO Cardiovascular Diseases (CVDs) Fact Sheet. no 317. 2012. 2014. [(accessed on 1 April 2023)]. Available online: https://aho.org/fact-sheets/cardiovascular-diseases-cvds-fact-sheet/
    1. Joseph P., Kutty V.R., Mohan V., Kumar R., Mony P., Vijayakumar K., Islam S., Iqbal R., Kazmi K., Rahman O., et al. Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: A PURE substudy. Eur. Hear. J. 2022;43:2831–2840. doi: 10.1093/eurheartj/ehac249. - DOI - PubMed
    1. Mensah G.A., Roth G.A., Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. American College of Cardiology Foundation; Washington, DC, USA: 2019. pp. 2529–2532. - PubMed
    1. Margolis K.L., Davis B.R., Baimbridge C., Ciocon J.O., Cuyjet A.B., Dart R.A., Einhorn P.T., Ford C.E., Gordon D., Hartney T.J., et al. Long-Term Follow-Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs. Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) J. Clin. Hypertens. 2013;15:542–554. doi: 10.1111/jch.12139. - DOI - PMC - PubMed
    1. Neutel J.M., Bestermann W.H., Dyess E.M., Alan G., Attila K., Santosh S., Carla Y. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: A randomized, placebo-controlled, multicenter study. J. Clin. Hypertens. 2009;11:22–30. doi: 10.1111/j.1751-7176.2008.00058.x. - DOI - PMC - PubMed

MeSH terms